Global Business Reports


Lucrezia Falcidia, Jason Spizer

United States Biopharmaceuticals 2020

May 15, 2020

Never before has the pharmaceutical industry faced greater challenges than now, as the whole world is looking to science for a solution to the COVID-19 global pandemic that can allow our societies to function once more. Much of this focus is naturally on the country that has been forcing back the boundaries of medicine like no other. The US is undoubtedly the world leader in bringing innovative therapeutics to market, and novel technologies currently being developed and commercialized are at record levels. An effective response to the COVID-19 pandemic requires unprecedented collaboration across academia, the private sector, and the philanthropic community. These are all areas in which the country excels. America, and in particular its leading clusters on the east coast, has a university system that is the envy of the world, as well as tech transfer, large pharma, fast growing biotech, important corporate partnerships, a well functioning incubator system, and an abundance of talent, skills and know-how regarding discovery, clinical trials and commercialization. These qualities, along with access to liquid and efficient capital markets, power the engine of the US biopharma industry.


Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.
Aphios’ vision is to develop biotechnology products for improving health and treating chronic diseases in an environmentally sustainable manner.
AzurRx BioPharma is a development stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions.
Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.


GBR speaks to Leopold Mboli Fatran, Minister of Mines and Geology of Central African Republic concerning the challenges of developing the country’s resource industries.